Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114904 | 1.00 | SOS1 (0.35) | SOS1DPP4JAK2JAK1IGF1R | |
| SCHEMBL2116093 | 0.90 | PIK3CD (0.35) | SOS1DPP4IDH1KCNN3PIK3CD | |
| SCHEMBL2116086 | 0.90 | PIK3CD (0.35) | SOS1DPP4IDH1KCNN3PIK3CD | |
| SCHEMBL2112940 | 0.89 | SOS1 (0.33) | SOS1DPP4IDH1KCNN3PIK3CD | |
| SCHEMBL2112939 | 0.89 | SOS1 (0.33) | SOS1DPP4IDH1KCNN3PIK3CD | |
| SCHEMBL2115348 | 0.88 | SOS1 (0.33) | SOS1DPP4 | |
| SCHEMBL2115350 | 0.88 | SOS1 (0.33) | SOS1DPP4 | |
| SCHEMBL2113787 | 0.88 | SOS1 (0.34) | SOS1DPP4IGF1RIDH1PIK3CD | |
| SCHEMBL2113779 | 0.88 | SOS1 (0.34) | SOS1DPP4IGF1RIDH1PIK3CD | |
| SCHEMBL2115950 | 0.85 | SOS1 (0.37) | SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | claimed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | SOS1 1776/4885DPP4 576/4885JAK2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.